Emerging strategies rely on engineering antibodies that can simultaneously target a tumor-associated antigen and a cell surface receptor of NK cells to facilitate antitumor activity by bringing immune cells in close proximity to tumor cells.12 The gene discussed is CD177; the disease is neoplasm.